Sequential treatment with vindesine–ifosfamide–platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: A phase II trial

摘要: Abstract Purpose : Daily administration of cisplatin concomitant with radiotherapy improved the overall survival in inoperable non-small cell lung cancer (NSCLC) one EORTC study. In this study, we prospectively investigated efficacy and toxicity a sequential treatment three cycles vindesine–ifosfamide–platinum (VIP) induction chemotherapy, followed by daily cisplatin-sensitized radiotherapy. Methods Between June 1993 1995, 23 previously untreated patients stage IIIB NSCLC World Health Organization performance status 0 or 1 were included. Chemotherapy consisted platinum 30 mg/m 2 ifosfamide 1200 i.v. on days 1, 3, vindesine 3 8, every 4 weeks. After at least stable disease, was started (30 Gy 10 fractions, boost 22 fractions). Each fraction preceded Platinum 6 Results Nineteen completed therapy. One patient died from neutropenic sepsis during first cycle had progressive disease after chemotherapy. The response rate therapy 47% (95% confidence interval 24–80), median 10.6 months, 1- 2-year rates 47 16%, respectively. Major neurotoxicity grade III–IV 18% leukopenia 22% patients. Acute radiation pneumonitis III occurred 11% Conclusion Three-drug VIP chemotherapy is feasible, acceptable, albeit substantial, toxicity. spite theoretically promising sequence therapies, results remain disappointingly low.